Baylor College of Medicine: CAR T Cell Therapy for Pediatric Brain Cancer Warrants Further Study
May 23, 2024
May 23, 2024
HOUSTON, Texas, May 23 (TNSres) -- The Baylor College of Medicine issued the following news:
Novel therapeutic approaches are needed for children with diffuse midline glioma (DMG) and other recurrent high-grade central nervous system (CNS) tumors, aggressive brain cancers with poor prognoses. A type of immunotherapy using T cells modified with chimeric antigen receptors (CAR T) has demonstrated efficacy in other cancers, but use in DMG and other CNS tumors has been limited.
Novel therapeutic approaches are needed for children with diffuse midline glioma (DMG) and other recurrent high-grade central nervous system (CNS) tumors, aggressive brain cancers with poor prognoses. A type of immunotherapy using T cells modified with chimeric antigen receptors (CAR T) has demonstrated efficacy in other cancers, but use in DMG and other CNS tumors has been limited.